Walleye Capital LLC Invests $3.44 Million in Evolus, Inc. (NASDAQ:EOLS)

Walleye Capital LLC bought a new stake in Evolus, Inc. (NASDAQ:EOLS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 212,209 shares of the company’s stock, valued at approximately $3,438,000. Walleye Capital LLC owned approximately 0.34% of Evolus at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Quest Partners LLC acquired a new position in shares of Evolus in the 2nd quarter valued at $43,000. Quarry LP bought a new stake in Evolus in the second quarter valued at about $54,000. Profund Advisors LLC acquired a new position in Evolus in the second quarter worth about $130,000. Arizona State Retirement System lifted its stake in Evolus by 9.4% during the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after purchasing an additional 1,253 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Evolus during the third quarter valued at approximately $191,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Barclays increased their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Friday, September 13th. HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Trading Down 1.3 %

EOLS stock opened at $13.51 on Tuesday. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market capitalization of $855.45 million, a price-to-earnings ratio of -14.85 and a beta of 1.31. The business has a fifty day moving average price of $15.22 and a 200 day moving average price of $13.88. Evolus, Inc. has a fifty-two week low of $9.38 and a fifty-two week high of $17.82.

Insider Activity

In related news, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This trade represents a 2.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 6.10% of the stock is currently owned by corporate insiders.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.